Eli Lilly and Company LLY is a leader in the fast-growing diabetes and obesity market, driven by its blockbuster ...

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry ...

Nektar Therapeutics NKTR reported a loss of $1.82 per share for the first quarter of 2026, wider than the Zacks Consensus ...

Eli Lilly is set to launch Lormalzi, a groundbreaking monthly injection targeting amyloid plaques for Alzheimer's treatment, ...

Eli Lilly said on Tuesday that patients in ​a late-stage trial who had been taking an injectable GLP-1 medication for over a ...

The prescription-only drug, Lormalzi can help the body remove the excessive buildup of amyloid plaques and slow the decline ...

Eli Lilly introduces Lormalzi in India, a new Alzheimer's therapy targeting amyloid plaques. Priced at Rs 91,688 per month.

Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...

Eli Lilly (LLY) stock is in focus as U.S. prescriptions for the company's obesity pill, Foundayo, top 7,000 during the fourth ...

India’s regulators are tightening oversight as obesity drug makers race to shape demand in the country’s emerging weight-loss ...

While Pfizer is playing catch-up in the GLP-1 race, it has several irons in the fire that could turn its business around.

Looking ahead to 2030, our model projects LLY could trade at an average price of $1,476.32, with a potential range between $1,107.24 and $1,845.40. This represents a potential 49.1% return from ...